[Aortic stenosis in the elderly: The TAVI revolution].
Le rétrécissement aortique de la personne très âgée : la révolution du TAVI.
Aged
Aortic Valve Stenosis
/ diagnostic imaging
Bioprosthesis
Heart Valve Prosthesis
Humans
Platelet Aggregation Inhibitors
/ therapeutic use
Postoperative Care
Postoperative Complications
/ prevention & control
Risk Assessment
Thrombosis
/ prevention & control
Transcatheter Aortic Valve Replacement
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
08
06
2018
revised:
28
09
2018
accepted:
07
11
2018
pubmed:
14
12
2018
medline:
11
4
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
TAVI is currently recommended for severe symptomatic aortic stenosis in patients at prohibitive, high or intermediate surgical risk as estimated by surgical risk scores (STS score and EuroSCORE II). Comorbidity, technical feasibility of TAVI and concurrent pathology with need for complementary surgical correction are conditions to be considered to choose between open surgery and TAVI. The decision is often made by the "Heart Team". The transfemoral access must be favored. Conduction disturbance, stroke, bioprosthesis thrombosis and durability are the main setbacks of TAVI. Double antiplatelet therapy with aspirin and clopidogrel during 3 to 6 months is currently recommended after TAVI, followed by long-term aspirin single therapy.
Identifiants
pubmed: 30545690
pii: S0755-4982(18)30453-6
doi: 10.1016/j.lpm.2018.11.007
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
165-172Informations de copyright
Copyright © 2018 Elsevier Masson SAS. All rights reserved.